Menu
Search
|

Menu

Close
X

Adverum Biotechnologies Inc ADVM.OQ (NASDAQ Stock Exchange Global Market)

5.10 USD
-0.17 (-3.32%)
As of 12:23 PM EDT
chart
Previous Close 5.28
Open 5.25
Volume 16,773
3m Avg Volume 154,808
Today’s High 5.25
Today’s Low 5.07
52 Week High 8.55
52 Week Low 2.45
Shares Outstanding (mil) 62.27
Market Capitalization (mil) 328.48
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
2
FY16
1
FY15
2
EPS (USD)
FY18
-0.300
FY17
-1.067
FY16
-3.208
FY15
-1.859
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.89
Price to Sales (TTM)
vs sector
204.92
8.00
Price to Book (MRQ)
vs sector
1.33
4.21
Price to Cash Flow (TTM)
vs sector
--
22.15
Total Debt to Equity (MRQ)
vs sector
0.00
17.41
LT Debt to Equity (MRQ)
vs sector
0.00
13.26
Return on Investment (TTM)
vs sector
-20.57
13.14
Return on Equity (TTM)
vs sector
-21.05
15.15

EXECUTIVE LEADERSHIP

Paul Cleveland
Chairman of the Board, Since 2017
Salary: $504,000.00
Bonus: --
Leone Patterson
Interim President and Chief Executive Officer, Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Mehdi Gasmi
Chief Science and Technology Officer, Since 2016
Salary: $385,000.00
Bonus: $103,333.00
Jennifer Cheng
Vice President, General Counsel, Since 2017
Salary: --
Bonus: --
Linda Neuman
Interim Chief Medical Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1035 Obrien Dr
MENLO PARK   CA   94025-1408

Phone: +1650.2726269
Site: adverum.com/

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing, specifically in process development and assay development.

SPONSORED STORIES